ArticleProceedings of the National Academy of Sciences of the United States of America2019
Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- A Mechanistic Clinical Trial Using (Circulation. Arrhythmia and electrophysiology · 2022Trial
- Selective RyR2 inhibition reduces arrhythmia susceptibility in human cardiac slices.The Journal of physiology · 2026Article
- The emerging role of calsequestrin 2: from calcium sensor and modulator to arrhythmia driver.Journal of physiology and biochemistry · 2026Review
- Cryo-EM Brings the Mechanisms of Activation, Inactivation, and Inhibition of Ryanodine Receptors into Focus.Advances in experimental medicine and biology · 2026Review
- Introduction of a single carboxylic acid converts the cyclic oligomeric depsipeptide ent-verticilide from a ryanodine receptor 2 (RyR2) inhibitor to RyR2 activator.Molecular pharmacology · 2025Article
- Preventing the phosphorylation of RyR2 at canonical sites reduces CaNature cardiovascular research · 2025Article
- End-to-End Backbone Cyclization Enhances Passive Permeability of bRo5 Oligomeric Depsipeptides with Nonlinear Size Dependence.ACS medicinal chemistry letters · 2025Article
- Backbone-Determined Antiarrhythmic Structure-Activity Relationships for a Mirror Image, Oligomeric Depsipeptide Natural Product.Journal of medicinal chemistry · 2024Article
- Article
- Clustering properties of the cardiac ryanodine receptor in health and heart failure.Journal of molecular and cellular cardiology · 2023Review
- RyR2 Binding of an Antiarrhythmic Cyclic Depsipeptide Mapped Using Confocal Fluorescence Lifetime Detection of FRET.ACS chemical biology · 2023Article
- Catecholaminergic Polymorphic Ventricular Tachycardia and Gene Therapy: A Comprehensive Review of the Literature.Cureus · 2023Review
- Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts.American journal of physiology. Heart and circulatory physiology · 2023Article
- RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease.Journal of molecular and cellular cardiology · 2023Article
- The selective RyR2 inhibitor ent-verticilide suppresses atrial fibrillation susceptibility caused by Pitx2 deficiency.Journal of molecular and cellular cardiology · 2023Article
- The intercalated disc: a unique organelle for electromechanical synchrony in cardiomyocytes.Physiological reviews · 2023Review
- RYR2-ryanodinopathies: from calcium overload to calcium deficiency.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic MoleculeThe Journal of pharmacology and experimental therapeutics · 2023Article
- Calcium Homeostasis, Transporters, and Blockers in Health and Diseases of the Cardiovascular System.International journal of molecular sciences · 2023Review
- Development of Ryanodine Receptor (RyR) Inhibitors for Skeletal Muscle and Heart Diseases.Juntendo Iji zasshi = Juntendo medical journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Suzanne M BatisteDepartment of Chemistry, Vanderbilt University, Nashville, TN 37235.
Daniel J BlackwellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Kyungsoo KimDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Dmytro O KryshtalDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Nieves Gomez-HurtadoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Robyn T RebbeckDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455.
Razvan L CorneaDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455.
Jeffrey N JohnstonDepartment of Chemistry, Vanderbilt University, Nashville, TN 37235; jeffrey.n.johnston@vanderbilt.edu bjorn.knollmann@vanderbilt.edu.ORCID 0000-0002-0885-636X
Bjorn C KnollmannDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232; jeffrey.n.johnston@vanderbilt.edu bjorn.knollmann@vanderbilt.edu.ORCID 0000-0003-4956-9735
Vanderbilt University Medical Center · USUniversity of Minnesota · USVanderbilt University · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MPathophysiological Regulation of Cardiac Myocyte RyR ChannelR01HL092097 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Donald M Bers, Robyn T Rebbeck · 2010 to 2026
$9.3MToward a Mechanism-Based Approach to Treating Cardiac ArrhythmiaR35HL144980 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2019 to 2025
$7.1MVanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3MStudies in Amide and Peptide SynthesisR01GM063557 · NIGMS · VANDERBILT UNIVERSITY · PI JOHNSTON, JEFFREY NICHOLAS · 2002 to 2022
$4.5MTRAINING PROGRAM IN ION CHANNEL AND TRANSPORTER BIOLOGYT32NS007491 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENTON, JEROD S. · 2001 to 2020
$4.1MCalsequestrin in Ventricular Arrhythmia and Sudden DeathR01HL088635 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2007 to 2015
$3.2MHigh-Throughput Screens to Discover Novel Inhibitors of Leaky RyR2 for Heart Failure TherapyR01HL138539 · NHLBI · UNIVERSITY OF MINNESOTA · PI BERS, DONALD M, CORNEA, RAZVAN LIVIU · 2018 to 2021
$3.1MNCI NIH HHS P30 CA068485NEI NIH HHS P30 EY008126NHLBI NIH HHS F32 HL140874NHLBI NIH HHS R01 HL088635NHLBI NIH HHS R01 HL092097NHLBI NIH HHS R01 HL124935NHLBI NIH HHS R01 HL128044NHLBI NIH HHS R01 HL138539NHLBI NIH HHS R35 HL144980NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIDDK NIH HHS U2C DK059637NIGMS NIH HHS R01 GM063557NIGMS NIH HHS R56 GM063557NINDS NIH HHS T32 NS007491
Abstract
Ca
Indexed as
AnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacCalciumCalcium Channel BlockersDepsipeptidesDimerizationMembrane PotentialsMiceRyanodineRyanodine Receptor Calcium Release ChannelStereoisomerismAnti-Arrhythmia AgentsCalciumCalcium Channel BlockersDepsipeptidesRyanodineRyanodine Receptor Calcium Release ChannelverticilidecardiomyocytesCPVTdepsipeptidenatural productryanodine receptor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.